Related Experiment Videos
Gene therapy in renal diseases
Enyu Imai1, Yoshitsugu Takabatake, Masayuki Mizui
1Division of Nephrology, Department of Internal Medicine, Osaka University Graduate School of Medicine, Japan. imai@medone.med.osaka-u.ac.jp
Kidney International
|April 17, 2004
Summary
Kidney-targeted gene therapy offers a promising approach for treating renal diseases by concentrating therapeutic molecules in the kidney. Advances in gene delivery and identification of disease-responsive genes are paving the way for hereditary disease treatments.
Area of Science:
- Nephrology
- Genetics
- Biotechnology
Background:
- Kidney-targeted gene therapy presents an ideal treatment strategy for renal diseases, minimizing systemic effects.
- Technical advancements in gene delivery to the kidney and identification of disease-responsive genes are crucial for treating hereditary kidney diseases.
- Successful collagen type IV reassembly in an Alport syndrome model via exogenous COL4A5 gene introduction demonstrates therapeutic potential.
Purpose of the Study:
- To review the current state and future prospects of gene therapy for various kidney diseases.
- To highlight the potential of gene therapy in treating hereditary renal diseases, glomerulonephritis, and transplant-related complications.
- To explore novel approaches like hybrid stem cell-gene therapy for advancing renal disease treatment.
Main Methods:
- Review of existing literature on gene therapy applications in preclinical models of kidney disease, including Alport syndrome, glomerulonephritis, and unilateral ureteral obstruction (UUO).
- Evaluation of gene therapy strategies targeting specific genes and pathways involved in renal pathology.
- Discussion of the potential of gene therapy in managing complications associated with kidney transplantation.
Main Results:
- Gene therapy has shown favorable results in various glomerulonephritis and unilateral ureteral obstruction (UUO) models.
- Successful collagen type IV gene transfer has been demonstrated in Alport syndrome models.
- Gene therapy holds promise for treating ischemia-reperfusion injury, acute rejection, and chronic allograft nephropathy in transplanted kidneys.
Conclusions:
- Kidney-targeted gene therapy is a promising avenue for treating a spectrum of renal diseases.
- Further development in gene delivery technologies and identification of therapeutic targets will accelerate clinical translation.
- Innovative strategies, such as hybrid stem cell-gene therapy, could significantly advance the treatment of kidney diseases.